DISCOVERY OF 3CL PROTEASE INHIBITOR by Dr Michael Levitt @InsilicoMedicine
DISCOVERY OF 3CL PROTEASE INHIBITOR by Dr Michael Levitt  @InsilicoMedicine
Uploaded May 2022 | Updated September 2026, 1 week ago
“ For me, to be able to describe a drug that would help alleviate the effects of COVID is actually a real pleasure and treat. It's remarkable that Insilico, without the resources of a major big pharma company, has abled to actually get a drug candidate for COVID in a very short period of time. They really seem to have a scheme, a method which is working not just once, but many times to basically speed up the development of drugs.” said Dr.Michael Levitt, 2013 Nobel Laureate in Chemistry.
DISCOVERY OF 3CL PROTEASE INHIBITOR by Dr Michael LevittTarget ID and Target Validation in PandaOmics 2.0A major update on ISM9528NVIDIA GTC Conference VideoInsilico Medicine at BIO 2022A Call for Longevity CollaborationLiquid AI x Insilico Launch LFM2-2.6B-MMAI (Live Demo)Longevity Lobster VS Longevity ClawInsilico Medicine Boston Office LaunchA Deep Dive into AI-Driven Longevity with Precious3GPT and PythonO3DC - Open Drug Discovery and Development Consortium Interview.Insilico MMAI Gym — Hook A Lab
Insilico Medicine |

DISCOVERY OF 3CL PROTEASE INHIBITOR by Dr Michael Levitt

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER